Aerovance is a biopharmaceutical company focused on the development and commercialization of clinical-stage products for respiratory and allergic diseases.
There are currently two lead products in clinical development: Aerovant™ for asthma is entering Phase IIb and Aeroderm™ for eczema in pre-clinical development. Other clinical stage products in Aerovance’s pipeline are Aerolytic™ for cystic fibrosis (CF) and Pulmolytic™ for chronic obstructive pulmonary disease (COPD).
The following trademarks are registered to Aerovance, Inc.:
